BoltzGen Democratizes AI Therapeutic Design, Expands Druggable Universe
The open-source model designs therapeutics across "any" modality with experimental validation for diverse real-world challenging targets.
By Fay Lin, PhD, the latest Boltz open-source model achieves this with experimental validation.
The Massachusetts Institute of Technology (MIT) research team debuted Boltz-1 in November 2024, a fully commercially available AI model to achieve AlphaFold 3-level accuracy in predicting the 3D structure of biomolecular complexes.
"any" modality with experimental validation for diverse real-world challenging targets
Author summary: BoltzGen expands AI therapeutic design.